Last updated on April 2016

A Phase 3 study to evaluate the safety and efficacy of iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens


Brief description of study

A Phase 3 study to evaluate the safety and efficacy of iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens

Detailed Study Description

The purpose of this study is to test the safety, tolerability and efficacy of the drug, iclaprim. It will be compared to vancomycin for the treatment of bacterial skin infections caused by bacteria called Gram-positive bacteria. Both these drugs are antibiotics (drugs that kill bacteria). Iclaprim is an experimental drug, which has not yet been approved by Health Authorities, such as the U.S. Food and Drug Administration (FDA). Vancomycin is an already approved antibiotic for the treatment of Gram-positive bacterial infections, including skin infections.

Iclaprim is an experimental antibiotic hoped to be effective in the treatment of severe infections caused by Gram-positive bacteria. Results of studies conducted so far with iclaprim show that it may work against bacteria that have developed resistance to many other antibiotics.

Clinical Study Identifier: TX143382

Contact Investigators or Research Sites near you

Start Over

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »